Clinical Trial Detail

NCT ID NCT02381314
Title Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MacroGenics
Indications

lung non-small cell carcinoma

melanoma

head and neck squamous cell carcinoma

Therapies

Ipilimumab + MGA271

Age Groups: adult

No variant requirements are available.